Remove Diagnostic Imaging Remove Radiation Remove Radiopharmaceuticals
article thumbnail

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.

article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Involve radiation safety early in your therapy center development. Involve radiation safety early in your therapy center development. "If

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

article thumbnail

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.

Clinic 98
article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 98
article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

An assistant professor of radiology and radiological science, Francis Deng, MD, is the Johns Hopkins radiology department's co-director of medical student diagnostic radiology electives. His area of expertise is neuroradiology, with a special emphasis on diagnostic imaging of the head, neck, brain, and spine. Elliot Fishman, MD.

article thumbnail

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3